{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:35:29Z","timestamp":1791279329377,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd007649.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,9,8]],"date-time":"2017-09-08T00:00:00Z","timestamp":1504828800000}}],"reference-count":160,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007649.pub4","type":"journal-article","created":{"date-parts":[[2017,9,8]],"date-time":"2017-09-08T09:16:44Z","timestamp":1504862204000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Certolizumab pegol (CDP870) for rheumatoid arthritis in adults"],"prefix":"10.1002","volume":"2017","author":[{"given":"Vicente","family":"Ruiz Garcia","sequence":"first","affiliation":[{"name":"La Fe University Hospital; Hospital at Home Unit, Tower C, Floor 1 Office 5 & CASPe Spain; Av Fernando Abril Martorell n\u00ba 106 Valencia Spain 46026"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Burls","sequence":"additional","affiliation":[{"name":"City University London; School of Health Sciences; Myddleton Street London UK EC1V 0HB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan B","family":"Cabello","sequence":"additional","affiliation":[{"name":"Hospital General Universitario de Alicante; Department of Cardiology & CASP Spain; Pintor Baeza 12 Alicante Alicante Spain 03010"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma","family":"Vela Casasempere","sequence":"additional","affiliation":[{"name":"Hospital General Universitario Alicante; Department of Rheumatology; Maestro Alonso, 109 Alicante Spain 03010"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Bort-Marti","sequence":"additional","affiliation":[{"name":"Acella Incubator; Avda Benjamin Franklin, 19 Paterna Spain 46980"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A","family":"Bernal","sequence":"additional","affiliation":[{"name":"Hospital General Universitario Alicante; Department of Rheumatology; Maestro Alonso, 109 Alicante Spain 03010"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,9,8]]},"reference":[{"key":"10.1002\/14651858.CD007649.pub4-BIB0001|cit1","doi-asserted-by":"crossref","unstructured":"Atsumi T Yamamoto K Takeuchi T Yamanaka H Ishiguro N Tanaka Y Baseline parameters identified in early, methotrexate-naive rheumatoid arthritis patients with better outcomes with certolizumab pegol+methotrexate compared to placebo+methotrexate: Post-hoc analyses of c-opera, a randomized, controlled, phase 3 study Annals of the Rheumatic Diseases.Conference: Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR 2015 Rome Italy. 10 - 13 June 2015 2015 716 7","DOI":"10.1136\/annrheumdis-2015-eular.1501"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0002|cit2","unstructured":"Atsumi T Yamamoto K Takeuchi T Yamanaka H Ishiguro N Tanaka Y Clinical benefit of 1-year certolizumab pegol treatment in MTX-na\u00efve, early rheumatoid arthritis patients is maintained after discontinuation up to 1 year Arthritis and Rheumatology.Conference: American College of Rheumatology\/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR\/ARHP 2015 San Francisco, CA United States. 6 - 11 November 2015 2015"},{"issue":"1","key":"10.1002\/14651858.CD007649.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/annrheumdis-2015-207511","article-title":"The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression","volume":"75","author":"Atsumi","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0004|cit4","doi-asserted-by":"crossref","unstructured":"Atsumi T Yamamoto K Takeuchi T Yamanaka H Ishiguro N Tanaka Y The first early rheumatoid arthritis, certolizumab pegol, multicenter, double-blind, randomized, parallel-group study: C-Opera, in patients fulfilling the 2010 ACR\/EULAR classification criteria, demonstrates inhibition of joint damage progression Annals of the Rheumatic Diseases.Conference: Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR 2014 Paris France. 11 - 14 June 2014 2014","DOI":"10.1136\/annrheumdis-2014-eular.1448"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0005|cit5","unstructured":"Atsumi T Yamamoto K Takeuchi T Yamanaka H Ishiguro N Tanaka Y The first, multicenter, double-blind, randomized, parallel-group study of certolizumab pegol in early rheumatoid arthritis demonstrates inhibition of joint damage progression Arthritis and Rheumatology.Conference: 2014 ACR\/ARHP Annual Meeting Boston, MA United States. 14 - 19 November 2014 2014 S1078 9"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0006|cit6","unstructured":"Emery P Smolen J Choy E CDP870 a novel, humanised tumour necrosis factor alpha inhibitor improves HRQOL. Late breaking abstract European League Against Rheumatism Annual Conference 2002"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0007|cit7","unstructured":"European Medicines Agency Assesment report for Cimzia. Procedure No EMEA\/H\/C\/001037 www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/001037\/WC500069735.pdf 1 47"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0008|cit8","unstructured":"Keystone E Choy E Kalden J Klareskog Sany J Smolen J CDP870, A novel pegylated, humanized TNF-alpha inhibitor, is effective in treating the signs and symptoms of rheumatoid arthritis (RA) Abstract to Rheumatology annual scientific meeting [abstract # LB-3] 2001"},{"issue":"10","key":"10.1002\/14651858.CD007649.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/rheumatology\/41.10.1133","article-title":"Efficacy of a novel pegylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial","volume":"41","author":"Choy","year":"2002","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1002\/14651858.CD007649.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/rheumatology\/ker519","article-title":"Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX","volume":"51","author":"Choy","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0011|cit11","unstructured":"UCB Clinical Study Summary Study No.: CDP870-014 www.ucb.com\/_up\/ucb_com_patients\/documents\/C87032_CSS_20080608.pdf"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0012|cit12","doi-asserted-by":"crossref","unstructured":"Emery P Bingham C Burmester GR Bykerk VP Furst D Mariette X Improvements in workplace and household productivity following 52 weeks of treatment with certolizumab pegol in combination with methotrexate in DMARD-naive patients with severe, active and progressive rheumatoid arthritis: Results from the c-early randomized, double-blind, controlled phase 3 study Value in Health.Conference: ISPOR 18th Annual European Congress Milan, Italy.Conference. 7 - 11 November 2015 2015 7","DOI":"10.1016\/j.jval.2015.09.2671"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0013|cit13","doi-asserted-by":"crossref","unstructured":"Emery P Bingham CO Burmester G-R Bykerk VP Furst DE Mariette X Improvements in patient-reported outcomes and workplace and household productivity following 52 weeks of treatment with certolizumab pegol in combination with methotrexate in DMARD-naive early rheumatoid arthritis patients: Results from the C-early randomized, double-blind, controlled phase 3 study Annals of the Rheumatic Diseases.Conference: Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR 2015 Rome Italy. 10 - 13 June 2015 2015 712 3","DOI":"10.1136\/annrheumdis-2015-eular.1499"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007649.pub4-BIB0014|cit14","first-page":"712","article-title":"SAT0165 Improvements in patient-reported outcomes and workplace and household productivity following 52 weeks of treatment with certolizumab pegol in combination with methotrexate in dmard-na\u00efve early rheumatoid arthritis patients: results from the C-Early randomized, double-blind, controlled phase 3 study","volume":"74","author":"Emery","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007649.pub4-BIB0015|cit15","first-page":"712","article-title":"sSAT0164 The first study of certolizumab pegol in combination with methotrexate in dmard-na\u00efve early rheumatoid arthritis patients led to Sustained clinical response and inhibition of radiographic progression at 52 weeks: The C-Early randomized, double-blind, controlled phase 3 study","volume":"74","author":"Emery","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0016|cit16","unstructured":"Weinblatt M Bingham C Burmester G Bykerk V Furst DE Mariette X Early response as a predictor of long-term remission in DMARD-naive patients with severe, active and progressive rheumatoid arthritis treated with certolizumab pegol in combination with methotrexate Arthritis and Rheumatology.Conference: American College of Rheumatology\/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR\/ARHP 2015 San Francisco, CA United States. 6 - 11 November 2015 2015"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0017|cit17","unstructured":"Weinblatt M Bingham C Burmester G Bykerk VP Furst DE Mariette X Certolizumab pegol in combination with methotrexate in DMARD-naive patients with active, severe, progressive rheumatoid arthritis: Results from a randomized, double-blind, controlled phase 3 study Arthritis and Rheumatology.Conference: American College of Rheumatology\/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR\/ARHP 2015 San Francisco, CA United States. 6 - 11 November 2015 2015"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0018|cit18","first-page":"169","article-title":"Efficacy and safety of certolizumab pegol monotherapy in patients with rheumatoid arthritis failing previous DMARD therapy","volume":"66 Suppl II","author":"Fleischmann","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0019|cit19","unstructured":"Fleischmann R Keininger DL Tahiri-Fitzgerald E Mease P Certolizumab pegol monotherapy 400mg every 4 weeks improves physical functioning and reduces pain in patients with rheumatoid arthritis Who have previously failed DMARD therapy Program and abstracts of the European League Against Rheumatism (EULAR) Annual Meeting; Barcelona, Spain 13-16 June [Abstract #0148] 2007"},{"issue":"6","key":"10.1002\/14651858.CD007649.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1136\/ard.2008.099291","article-title":"Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease modifying antirheumatic therapy: the FAST4WARD study","volume":"68","author":"Fleischmann","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0021|cit21","unstructured":"Keystone E Mason D Fleischmann R Certolizumab pegol 400 mg every 4 weeks as monotherapy rapidly reduces disease activity in active rheumatoid arthritis Program and abstracts of the American College of Rheumatology (ACR) 71st Annual Meeting; November 6 - 11; Boston, Massachusetts. [Abstract #277] 2007"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0022|cit22","unstructured":"Strand V Brown M Purcaru O Richard L Certolizumab pegol monotherapy improves productivity in patients with active rheumatoid arthritis: results from a phase III randomized controlled trial Program and abstracts of the European League Against Rheumatism (EULAR) Annual Meeting; Barcelona, Spain 13 - 16 June [Abstract #0478] 2007"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0023|cit23","unstructured":"Strand V Keininger D Tahiri-Fitzgerald E Fleischmann R Certolizumab pegol monotherapy 400mg every 4 weeks improves health-related quality of life and relieves fatigue in patients with rheumatoid arthritis who have previously failed DMARD therapy Program and abstracts of the European League Against Rheumatism (EULAR) Annual Meeting; Barcelona, Spain 13 - 16 June [Abstract #0205] 2007"},{"issue":"8","key":"10.1002\/14651858.CD007649.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/art.30387","article-title":"Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data","volume":"63","author":"Curtis","year":"2011","journal-title":"Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD007649.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/acr.21600","article-title":"Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 year","volume":"64","author":"Curtis","year":"2012","journal-title":"Arthritis Care Research (Hoboken)"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0026|cit26","unstructured":"Haraoui B Bykerk VP Van Vollenhoven R De Longueville M Luijtens K Ralston P Analysis of pooled data from two randomized controlled trials and their open-label extensions: Long-term safety in rheumatoid arthritis before and after certolizumab pegol dose increase\/decrease Arthritis and Rheumatology.Conference: 2014 ACR\/ARHP Annual Meeting Boston, MA United States 14 - 19 N0vember 2014 2014 S199"},{"issue":"11","key":"10.1002\/14651858.CD007649.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1002\/art.23964","article-title":"Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"58","author":"Keystone","year":"2008","journal-title":"Arthritis and Rheumatism"},{"issue":"12","key":"10.1002\/14651858.CD007649.pub4-BIB0028|cit28","first-page":"A228","article-title":"5-Year results from the RAPID 1 trial and open-label extension: long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis","volume":"72","author":"Keystone","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0029|cit29","doi-asserted-by":"crossref","unstructured":"Keystone E Landew\u00e9 R Van Vollenhoven R Combe B Strand V Mease P Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from a 52-week randomized controlled trial and open-label extension study Journal of Rheumatology Conference: 69th Annual Meeting of the Canadian Rheumatology Association, CRA 2014 Whistler, BC Canada. 24 February - 1 March 2014 2014 7","DOI":"10.1093\/rheumatology\/keu101.024"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0030|cit30","first-page":"S988","article-title":"Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension","volume":"65","author":"Keystone","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0031|cit31","unstructured":"Keystone E Mason D Combe B The anti-TNF certolizumab pegol in combination with methotrexate is significantly more effective than methotrexate alone in the treatment of patients with active rheumatoid arthritis: 1-year results from the RAPID 1 study Program and abstracts of the American College of Rheumatology (ACR) 71st Annual Meeting; 6 - 11 November 2007; Boston, Massachusetts [Abstract #700] 2007"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/rheumatology\/kes082","article-title":"Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial","volume":"51","author":"Keystone","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0033|cit33","unstructured":"NCT00175877 A study of the safety and effectiveness of lyophilized certolizumab pegol in the treatment of signs and symptoms of rheumatoid arthritis and in prevention of joint damage in patients with active rheumatoid arthritis clinicaltrials.gov\/ct2\/show\/NCT00175877"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0034|cit34","unstructured":"Strand V Keininger DL Tahiri-Fizgerald E Certolizumab pegol results in clinically meaningful improvements in physical function and health-related quality of life in patients with active rheumatoid arthritis despite treatment with methotrexate Program and abstracts of the American College of Rheumatology (ACR) 71st Annual Meeting; 6 - 11 November 2007; Boston, Massachusetts. [Abstract #946] 2007"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0035|cit35","doi-asserted-by":"crossref","unstructured":"Strand V Mease P Burmester G Nika\u00ef E Coteur G Vollenhoven R Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial Arthritis Research & Therapy 2009 R170","DOI":"10.1186\/ar2859"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0036|cit36","unstructured":"UCB Preliminary results suggest certolizumab pegol plus methotrexate is effective in reducing signs and symptoms of rheumatoid arthritis in patients refractory to methotrexate. Results from the RAPID 1 Study. Abstract number: OPO016 EULAR 2007 2007"},{"issue":"7","key":"10.1002\/14651858.CD007649.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3899\/jrheum.111171","article-title":"Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial","volume":"39","author":"Heijde","year":"2012","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0038|cit38","unstructured":"Van der Heijde D Strand V Keystone E Landew\u00e9 R Inhibition of radiographic progression by lyophilized certolizumab pegol added to methotrexate in comparison with methotrexate alone in patients with rheumatoid arthritis: the RAPID 1 trial Program and abstracts of the American College of Rheumatology (ACR) 71st Annual Meeting; November 6-11; Boston, Massachusetts. [Abstract #940] 2007"},{"issue":"9 Suppl","key":"10.1002\/14651858.CD007649.pub4-BIB0039|cit39","first-page":"529","article-title":"Inhibition of progression of structural damage by week 16 with certolizumab pegol: Results from the RAPID trials","volume":"58","author":"Heijde","year":"2008","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0040|cit40","unstructured":"NCT00993317 A study of CDP870 as add-on medication to methotrexate (MTX) in patients with rheumatoid arthritis clinicaltrials.gov\/ct2\/show\/study\/NCT00993317"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0041|cit41","unstructured":"Haraoui B Bykerk VP Van Vollenhoven R De Longueville M Luijtens K Ralston P Analysis of pooled data from two randomized controlled trials and their open-label extensions: Long-term safety in rheumatoid arthritis before and after certolizumab pegol dose increase\/decrease Arthritis and Rheumatology.Conference: 2014 ACR\/ARHP Annual Meeting Boston, MA United States 14 - 19 N0vember 2014 2014 S199"},{"issue":"11","key":"10.1002\/14651858.CD007649.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/art.24828","article-title":"Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis","volume":"61","author":"Kavanaugh","year":"2009","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0043|cit43","unstructured":"Landew\u00e9 R Strand V Smolen J Van der Heijde D Liquid formulation certolizumab pegol with methotrexate decreases progression of structural joint damage in rheumatoid arthritis patients: the RAPID 2 study Program and abstracts of the American College of Rheumatology (ACR) 71st Annual Meeting; 6 - 11 November 2007; Boston, Massachusetts. [Abstract #696] 2007"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0044|cit44","unstructured":"Mease P Mason D Kavanaugh A Smolen J Efficacy and rapid response of certolizumab pegol liquid formulation in combination with methotrexate (MTX) in patients with active rheumatoid arthritis despite MTX therapy: results from the RAPID 2 study Program and abstracts of the American College of Rheumatology (ACR) 71st Annual Meeting; 6 - 11 November 2007; Boston, Massachusetts. [Abstract #941] 2007"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0045|cit45","unstructured":"Schiff M Keininger DL Tahiri-Fitzgerald E Certolizumab pegol added onto methotrexate improves physical functioning and reduces pain in patients with rheumatoid arthritis who have an incomplete response to methotrexate: data from rapid 2 Program and abstracts of the European League Against Rheumatism (EULAR) Annual Meeting; Barcelona, Spain 13 - 16 June [Abstract #0200] 2007"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0046|cit46","unstructured":"Smolen J Brzezicki J Mason D Kavanaugh A Efficacy and safety of certolizumab pegol in combination with methotrexate (mtx) in patients with active rheumatoid arthritis despite MTX therapy: results from the Rapid 2 study Program and abstracts of the European League Against Rheumatism (EULAR) Annual Meeting; Barcelona, Spain 13 - 16 June [Abstract #0202] 2007"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/ard.2008.101659","article-title":"Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial","volume":"68","author":"Smolen","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13075-015-0767-2","article-title":"Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients","volume":"17","author":"Smolen","year":"2015","journal-title":"Arthritis Research & Therapy"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0049|cit49","unstructured":"Strand V Keininger DL Tahiri-Fizgerald E Certolizumab pegol results in clinically meaningful improvements in physical function and health-related quality of life in patients with active rheumatoid arthritis despite treatment with methotrexate Program and abstracts of the European League Against Rheumatism (EULAR) Annual Meeting; Barcelona, Spain 13 - 16 June 2007 [Abstract #0335] 2007"},{"issue":"6","key":"10.1002\/14651858.CD007649.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/ard.2010.143586","article-title":"Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial","volume":"70","author":"Strand","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0051|cit51","unstructured":"NCT00674362 Rheumatoid arthritis (RA) moderate to low disease activity study (CERTAIN) clinicaltrials.gov\/ct2\/show\/NCT00674362"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0052|cit52","first-page":"361","article-title":"Maintenance of remission in rheumatoid arthritis patients with low-moderate disease activity following withdrawal of certolizumab PEGOL treatment: Week 52 results from the certain study","volume":"71 Suppl 3","author":"Smolen","year":"2013","journal-title":"Annals of the Rheumatic Disease"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0053|cit53","doi-asserted-by":"crossref","unstructured":"Smolen JS Emery P Ferraccioli GF Samborski W Berenbaum F Davies OR Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial Annals of the Rheumatic Diseases 2015 843 50 10.1136\/annrheumdis-2013-204632","DOI":"10.1136\/annrheumdis-2013-204632"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13075-015-0767-2","article-title":"Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients","volume":"17","author":"Smolen","year":"2015","journal-title":"Arthritis Research & Therapy"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s13075-015-0849-1","article-title":"Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity","volume":"17","author":"Pope","year":"2015","journal-title":"Arthritis Research & Therapy"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/rheumatology\/kes150","article-title":"Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study","volume":"51","author":"Weinblatt","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s13075-015-0841-9","article-title":"Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population","volume":"17","author":"Weinblatt","year":"2015","journal-title":"Arthritis Research & Therapy"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0058|cit58","unstructured":"NCT00791921 Efficacy confirmation trial of CDP870 without coadministration of methotrexate (MTX) in Japanese rheumatoid arthritis (RA) clinicaltrials.gov\/show\/NCT00791921"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0059|cit59","unstructured":"NCT00850343 Long-term treatment study of certolizumab pegol without coadministration of methotrexate in Japanese rheumatoid arthritis (RA) patients clinicaltrials.gov\/ct2\/show\/NCT00850343?term=NCT00850343&rank=1"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0060|cit60","unstructured":"Takeuchi T Yamamoto K Yamanaka H Ishiguro N Tanaka Y Eguchi K Better clinical responses seen early with the loading dose of certolizumab pegol are maintained until one year Annals of the Rheumatic Diseases.Conference: Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR 2014 Paris France. 11 - 14 June 2014 2014"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0061|cit61","doi-asserted-by":"crossref","unstructured":"Tanaka Y Yamamoto K Takeuchi T Yamanaka H Ishiguro N Eguchi K Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study Modern Rheumatology 2013 725 33 10.3109\/14397595.2013.865822","DOI":"10.3109\/14397595.2013.865822"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3109\/14397595.2013.843764","article-title":"Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: The HIKARI randomized, placebo-controlled trial","volume":"24","author":"Yamamoto","year":"2014","journal-title":"Modern Rheumatology"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0063|cit63","first-page":"664","article-title":"AB0469. Improved physical function, pain, and health related quality of life with certolizumab pegol in Japanese rheumatoid arthritis patients without methotrexate co-administration:results from the Hikari study","volume":"71 Suppl 3","author":"Yamanaka","year":"2013","journal-title":"Annals of the Rheumaic Diseases"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0064|cit64","first-page":"S83","article-title":"Certolizumab pegol improved physical function and heath related quality of life in patients with active rheumatoid arthritis who could not be treated with methotrexate: results form HIKARI study","volume":"22 Suppl ll","author":"Yamanaka","year":"2012","journal-title":"Modern Rheumatology"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0065|cit65","unstructured":"NCT00791999 Efficacy confirmation trial of CDP870 as add-on medication to methotrexate (MTX) in Japanese rheumatoid arthritis (RA) clinicaltrials.gov\/ct2\/show\/study\/NCT00791999?term=NCT00791999&rank=1"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0066|cit66","unstructured":"Takeuchi T Yamamoto K Yamanaka H Ishiguro N Tanaka Y Eguchi K Better clinical responses seen early with the loading dose of certolizumab pegol are maintained until one year Annals of the Rheumatic Diseases.Conference: Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR 2014 Paris France. 11 - 14 June 2014 2014"},{"issue":"5","key":"10.1002\/14651858.CD007649.pub4-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3109\/14397595.2014.881709","article-title":"Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study","volume":"24","author":"Tanaka","year":"2014","journal-title":"Modern Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD007649.pub4-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3109\/14397595.2013.864224","article-title":"Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial","volume":"24","author":"Yamamoto","year":"2014","journal-title":"Modern Rheumatology"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1136\/annrheumdis-2012-eular.468","article-title":"AB0468\u2005Improved physical function, pain, and health related quality of life with certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: Results from the JRapid study","volume":"71 Suppl 3","author":"Yamanaka","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0070|cit70","first-page":"S83","article-title":"Certolizumab pegol improved physical function and heath related quality of life in patients with active Rheumatoid Arthritis despite treatment with methotrexate: results form the JRAPID study","volume":"22 Suppl ll","author":"Yamanaka","year":"2012","journal-title":"Modern Rheumatology"},{"issue":"pp S518-S519","key":"10.1002\/14651858.CD007649.pub4-BIB0071|cit71","first-page":"October","article-title":"Dynamic magnetic resonance imaging in the assessment of the response to certolizumab pegol in rheumatoid arthritis patients: Results from a phase IIIB randomized study","volume":"66","author":"\u00d8stergaard","year":"2014","journal-title":"Arthritis and Rheumatology.Conference: 2014 ACR\/ARHP Annual Meeting Boston, MA United States.Conference Start: 20141114 Conference End: 20141119.Conference Publication: (var.pagings)"},{"issue":"6","key":"10.1002\/14651858.CD007649.pub4-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/annrheumdis-2014-206359","article-title":"MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16","volume":"74","author":"\u00d8stergaard","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0073|cit73","first-page":"111","article-title":"Long term tolerability and efficacy of a 4-week-administration of certolizumab pegol as monotherapy and combination therapy in rheumatoid arthritis; 5-year-data of an open extension study","volume":"72","author":"Alten","year":"2013","journal-title":"Zeitschrift F\u00fcr Rheumatologie"},{"issue":"no pagination","key":"10.1002\/14651858.CD007649.pub4-BIB0074|cit74","first-page":"October","article-title":"Reduction of disease burden on workplace and household productivity following 52 weeks of treatment with certolizumab pegol in combination with methotrexate in DMARD-naive patients with active, severe, progressive rheumatoid arthritis","volume":"67","author":"Bykerk","year":"2015","journal-title":"Arthritis and Rheumatology.Conference: American College of Rheumatology\/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR\/ARHP 2015 San Francisco, CA United States.Conference Start: 20151106 Conference End: 20151111.Confer"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0075|cit75","doi-asserted-by":"crossref","unstructured":"Curtis JR Churchill M Kivitz A Samad A Gauer L Coteur G Randomization to patient-reported RAPID3 versus physician-based CDAI tools for prediction of treatment response and assessment of patient-reported outcomes in rheumatoid arthritis patients receiving certolizumab pegol: Results from the predict study Annals of the Rheumatic Diseases.Conference: Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR 2014 Paris France. 11 -14 June 2014 2014","DOI":"10.1136\/annrheumdis-2014-eular.1674"},{"issue":"12","key":"10.1002\/14651858.CD007649.pub4-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1002\/art.39322","article-title":"A randomized trial comparing disease activity measures for the assessment and prediction of response in rheumatoid arthritis patients initiating certolizumab pegol","volume":"67","author":"Curtis","year":"2015","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0077|cit77","unstructured":"Curtis JR De Longueville M O'Brien C Haraoui B Improvement in disease activity and the long-term risk of serious infectious events in rheumatoid arthritis patients treated with certolizumab pegol Arthritis and Rheumatology.Conference: American College of Rheumatology\/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR\/ARHP 2015 San Francisco, CA United States. 6 - 11 November 2015 2015"},{"issue":"2","key":"10.1002\/14651858.CD007649.pub4-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/acr.22496","article-title":"Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis","volume":"67","author":"Furst","year":"2015","journal-title":"Arthritis Care & Research"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0079|cit79","unstructured":"NCT00580840 Dosing flexibility study in patients with rheumatoid arthritis (DoseFlex) clinicaltrials.gov\/ct2\/show\/results\/NCT00580840"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/annrheumdis-2013-eular.1313","article-title":"Long-term safety and efficacy of 4-weekly certolizumab pegol monotherapy and combination therapy in rheumatoid arthritis: 5-year results from an open-label extension study","volume":"72","author":"Fleischmann","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0081|cit81","first-page":"A570","article-title":"Long-term benefits over more than 4 years of certolizumab pegol combination therapy on workplace and household productivity, and participation in social activities in rheumatoid arthritis: Results from the open-label extension study","volume":"16","author":"Kavanaugh","year":"2013","journal-title":"Value in Health"},{"issue":"3","key":"10.1002\/14651858.CD007649.pub4-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"A53","DOI":"10.1016\/j.jval.2014.03.311","article-title":"PMS66 - Effect of certolizumab pegol on workplace And household productivity In United States patients with rheumatoid arthritis with or without prior anti-Tnf exposure: results from the Predict study","volume":"17","author":"Kavanaugh","year":"2014","journal-title":"Value in Health"},{"issue":"4","key":"10.1002\/14651858.CD007649.pub4-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3899\/jrheum.130945","article-title":"Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial","volume":"41","author":"Kivitz","year":"2014","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0084|cit84","unstructured":"NCT00160641 A study of the safety and effectiveness of liquid certolizumab pegol in the treatment of signs and symptoms of rheumatoid arthritis and in prevention of joint damage in patients with active rheumatoid arthritis clinicaltrials.gov\/ct2\/show\/NCT00160641?term=NCT00160641&rank=1"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0085|cit85","unstructured":"NCT00160693 Open label long-term safety study of certolizumab pegol (CZP) for patients with rheumatoid arthritis clinicaltrials.gov\/ct2\/show\/NCT00160693"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0086|cit86","unstructured":"NCT00753454 Open label extension for patients coming from the dosing flexibility study in patients with rheumatoid arthritis (RA) (Dose Flex II) clinicaltrials.gov\/ct2\/show\/NCT00753454?term=NCT00753454&rank=1"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0087|cit87","unstructured":"NCT00843778 Follow-up of rheumatoid arthritis (RA) moderate to low disease activity study (CERTAIN 2) clinicaltrials.gov\/ct2\/show\/NCT00843778?term=NCT00843778&rank=1"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0088|cit88","unstructured":"NCT00851318 Long-term treatment study of certolizumab pegol (CDP870) as add-on medication to methotrexate in Japanese rheumatoid arthritis (RA) Patients clinicaltrials.gov\/ct2\/show\/NCT00851318?term=certolizumab+and+arthritis&lup_s=01%2F01%2F2013&lup_e=03%2F01%2F2016&rank=11"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0089|cit89","unstructured":"NCT00993668 Assessing the use of certolizumab pegol in adult subjects with rheumatoid arthritis on the antibody response when receiving influenza virus and pneumococcal vaccines clinicaltrials.gov\/ct2\/show\/results\/NCT00993668?term=NCT00993668&rank=1"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0090|cit90","unstructured":"NCT01197066 Open-label, extension study of CDP870 in patients with rheumatoid arthritis clinicaltrials.gov\/ct2\/show\/NCT01197066?"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0091|cit91","unstructured":"NCT01255761 A comparison of two assessment tools in predicting treatment success of cimzia in rheumatoid arthritis subjects (PREDICT) clinicaltrials.gov\/ct2\/show\/NCT01255761?term=NCT01255761&rank=1"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0092|cit92","unstructured":"NCT01292265 A 12 week study to assess changes in joint inflammation using ultrasonography in patients with rheumatoid arthritis (RA) clinicaltrials.gov\/ct2\/show\/NCT01292265?term=certolizumab+and+arthritis&lup_s=01%2F01%2F0201&lup_e=03%2F01%2F2016&rank=25"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0093|cit93","unstructured":"NCT01374971 Rheumatoid arthritis treatment and biopsy study assessing certolizumab pegol (Cimzia) clinicaltrials.gov\/ct2\/show\/results\/NCT01374971?term=NCT01374971&rank=1"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0094|cit94","unstructured":"NCT01443364 Open label study to assess the predictability of early response to certolizumab pegol in patients with rheumatoid arthritis (SPEED) clinicaltrials.gov\/ct2\/show\/NCT01443364?term=certolizumab+and+arthritis&lup_s=01%2F01%2F2013&lup_e=03%2F01%2F2016&rank=13"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0095|cit95","unstructured":"NCT01526434 Health-related quality of life and patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol clinicaltrials.gov\/ct2\/show\/NCT01526434?term=certolizumab+and+arthritis&lup_s=01%2F01%2F0201&lup_e=03%2F01%2F2016&rank=28"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0096|cit96","unstructured":"NCT02319642 An open-label extension study of certolizumab pegol in Chinese patients with rheumatoid arthritis who enrolled in RA0044 (RAPID-C OLE) clinicaltrials.gov\/ct2\/show\/NCT02319642?term=certolizumab+and+arthritis&lup_s=01%2F01%2F2013&lup_e=03%2F01%2F2016&rank=4"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0097|cit97","unstructured":"NCT02586246 Long-term treatment study of CDP870 self-injection in patients with active rheumatoid arthritis who are participating in the long-term treatment studies (Study 275-08-002 or Study 275-08-004) of CDP870 clinicaltrials.gov\/ct2\/show\/NCT02586246?term=certolizumab+and+arthritis&lup_s=01%2F01%2F0201&lup_e=03%2F01%2F2016&rank=24"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0098|cit98","unstructured":"NCT01295151 SWITCH clinical trial for patients with rheumatoid arthritis who have failed an initial TNF-blocking drug (SWITCH) clinicaltrials.gov\/ct2\/show\/NCT01295151"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0099|cit99","doi-asserted-by":"crossref","unstructured":"Navarro C Nuria C Brown S Bosworth A The 'Switch\u2019 study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug BMC Musculoskeletal Disorders 2014 452 10.1186\/1471-2474-15-452","DOI":"10.1186\/1471-2474-15-452"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0100|cit100","unstructured":"NCT01489384 Cimzia treatment in rheumatoid arthritis: randomizing to stop versus continue disease-modifying anti-rheumatic drug(s) clinicaltrials.gov\/ct2\/show\/NCT01489384?term=certolizumab+and+arthritis&lup_s=01%2F01%2F0201&lup_e=03%2F01%2F2016&rank=45"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0101|cit101","unstructured":"NCT01491815 Active conventional therapy compared to three different biologic treatments in early rheumatoid arthritis with subsequent dose reduction clinicaltrials.gov\/ct2\/show\/NCT01491815?term=certolizumab+and+arthritis&lup_s=01%2F01%2F0201&lup_e=03%2F01%2F2016&rank=51"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0102|cit102","unstructured":"NCT01500278 Study to assess the short- and long-term efficacy of certolizumab pegol plus methotrexate compared to adalimumab plus methotrexate in subjects with moderate to severe rheumatoid arthritis (RA) inadequately responding to methotrexate clinicaltrials.gov\/ct2\/show\/NCT01500278?term=certolizumab+and+arthritis&lup_s=01%2F01%2F2013&lup_e=03%2F01%2F2016&rank=17"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0103|cit103","unstructured":"NCT01602302 Ultrasound and withdrawal of biological DMARDs in rheumatoid arthritis clinicaltrials.gov\/ct2\/show\/NCT01602302?term=certolizumab+and+arthritis&lup_s=01%2F01%2F0201&lup_e=03%2F01%2F2016&rank=48"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0104|cit104","unstructured":"NCT02151851 A study of certolizumab pegol as additional therapy in Chinese patients with active rheumatoid arthritis (RAPID-C) clinicaltrials.gov\/ct2\/show\/NCT02151851?term=certolizumab+and+arthritis&lup_s=01%2F01%2F2013&lup_e=03%2F01%2F2016&rank=18"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0105|cit105","unstructured":"NCT02293590 RICE: Remission by Intra-articular Injection Plus Certolizumab clinicaltrials.gov\/ct2\/show\/NCT02293590?term=certolizumab+and+arthritis&lup_s=01%2F01%2F0201&lup_e=03%2F01%2F2016&rank=50"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0106|cit106","unstructured":"NCT02430909 Multiple dose study of UCB4940 as add-on to certolizumab pegol in subjects with rheumatoid arthritis clinicaltrials.gov\/ct2\/show\/NCT02430909?term=certolizumab+and+arthritis&lup_s=01%2F01%2F0201&lup_e=03%2F01%2F2016&rank=34"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0107|cit107","unstructured":"NCT02466581 Dose reduction for early rheumatoid arthritis patients with low disease activity clinicaltrials.gov\/ct2\/show\/NCT02466581?term=certolizumab+and+arthritis&lup_s=01%2F01%2F0201&lup_e=03%2F01%2F2016&rank=42"},{"issue":"5","key":"10.1002\/14651858.CD007649.pub4-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.semarthrit.2015.10.016","article-title":"Influence of demographic and clinical factors on the mortality rate of a rheumatoid arthritis cohort: A 20-year survival study","volume":"45","author":"Abasolo","year":"2016","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD007649.pub4-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD007649.pub4-BIB0110|cit110","first-page":"477","article-title":"Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials","volume":"170","author":"Bhandari","year":"2004","journal-title":"Canadian Medical Association Journal"},{"issue":"3","key":"10.1002\/14651858.CD007649.pub4-BIB0111|cit111","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003785","article-title":"Infliximab for the treatment of rheumatoid arthritis","author":"Blumenauer","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"19","key":"10.1002\/14651858.CD007649.pub4-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"issue":"11","key":"10.1002\/14651858.CD007649.pub4-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1172\/JCI36389","article-title":"Evidence that cytokines play a role in rheumatoid arthritis","volume":"118","author":"Brennan","year":"2008","journal-title":"The Journal of Clinical Investigation"},{"issue":"1","key":"10.1002\/14651858.CD007649.pub4-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/annrheumdis-2013-203660","article-title":"Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials","volume":"74","author":"Bykerk","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0115|cit115","doi-asserted-by":"crossref","unstructured":"Chen YF Jobanputra P Barton P Jowett S Bryan S Clark W A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness Health Technology Assessment 2006 1 235","DOI":"10.3310\/hta10420"},{"issue":"7","key":"10.1002\/14651858.CD007649.pub4-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1136\/annrheumdis-2013-204627","article-title":"The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study","volume":"73","author":"Cross","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/art.509","article-title":"Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD007649.pub4-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/annrheumdis-2016-209166","article-title":"The changing landscape of biosimilars in rheumatology","volume":"75","author":"D\u00f6rner","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0119|cit119","unstructured":"European Medical Agency Assesment report for Cimzia. Procedure No EMEA\/H\/C\/001037 www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/001037\/WC500069735.pdf 1 47"},{"issue":"6","key":"10.1002\/14651858.CD007649.pub4-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/jep.12460","article-title":"Does evidence-based practice improve patient outcomes? An analysis of a natural experiment in a Spanish hospital","volume":"21","author":"Emparanza","year":"2015","journal-title":"Journal of Evaluation in Clinical Practice"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0121|cit121","unstructured":"Center for Drug Evaluation and Research Postmarket Drug Safety Information for Patients and Providers - Information for Healthcare Professionals: Cimzia (certolizumab pegol), Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab) www.fda.gov\/drugs\/drugsafety\/postmarketdrugsafetyinformationforpatientsandproviders\/ucm124185.htm"},{"issue":"3","key":"10.1002\/14651858.CD007649.pub4-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/art.30129","article-title":"American College of Rheumatology\/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"63","author":"Felson","year":"2011","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD007649.pub4-BIB0123|cit123","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"Journal of the Medical Library Association"},{"issue":"10","key":"10.1002\/14651858.CD007649.pub4-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/rheumatology\/keq109","article-title":"Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol","volume":"49","author":"Hazes","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0125|cit125","unstructured":"Higgins JP Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"issue":"6","key":"10.1002\/14651858.CD007649.pub4-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"e001395","DOI":"10.1136\/bmjopen-2012-001395","article-title":"A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non inferiority study of first TNF inhibitor use: outcomes over 2 years","volume":"2","author":"Jobanputra","year":"2012","journal-title":"BMJ Open"},{"issue":"9","key":"10.1002\/14651858.CD007649.pub4-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/rheumatology\/kes082","article-title":"Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial","volume":"51","author":"Keystone","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1002\/14651858.CD007649.pub4-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/art.39491","article-title":"Antibodies to Porphyromonas gingivalis Indicate Interaction Between Oral Infection, Smoking, and Risk Genes in Rheumatoid Arthritis Etiology","volume":"68","author":"Kharlamova","year":"2016","journal-title":"Arthritis & Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD007649.pub4-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0197-2456(90)90018-W","article-title":"Estimating rates of change in randomized clinical trials","volume":"11","author":"Laird","year":"1990","journal-title":"Controlled Clinical Trials"},{"issue":"26","key":"10.1002\/14651858.CD007649.pub4-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJM198806303182605","article-title":"An assessment of clinically useful measures of the consequences of treatment","volume":"318","author":"Laupacis","year":"1988","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD007649.pub4-BIB0131|cit131","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004525.pub2","article-title":"Etanercept for the treatment of rheumatoid arthritis","author":"Lethaby","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD007649.pub4-BIB0132|cit132","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000957.pub2","article-title":"Methotrexate for treating rheumatoid arthritis","author":"Lopez-Olivo","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD007649.pub4-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1136\/annrheumdis-2012-201484","article-title":"Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein\/peptide antibody fine specificity profile","volume":"72","author":"Lundberg","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD007649.pub4-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B","article-title":"Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins","volume":"43","author":"MacGregor","year":"2000","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1093\/rheumatology\/kep252","article-title":"Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies","volume":"48","author":"Meune","year":"2009","journal-title":"Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD007649.pub4-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"384-90","DOI":"10.1097\/BOR.0b013e32835fc62e","article-title":"Newest clinical trial results with antitumor necrosis factor and non antitumor necrosis factor biologics for rheumatoid arthritis","volume":"25","author":"Navarro-Mill\u00e1n","year":"2013","journal-title":"Current Opinion in Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD007649.pub4-BIB0137|cit137","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005113.pub2","article-title":"Adalimumab for treating rheumatoid arthritis","author":"Navarro-Sarabia","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0138|cit138","unstructured":"UCB Certolizumab pegol (CIMZIA\u00a9) for the treatment of rheumatoid arthritis. Single technology appraisal (STA) manufacturer submission to NICE NICE 2009 1 180"},{"issue":"7488","key":"10.1002\/14651858.CD007649.pub4-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nature12873","article-title":"Genetics of rheumatoid arthritis contributes to biology and drug discovery","volume":"506","author":"Okada","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1002\/14651858.CD007649.pub4-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/art.20716","article-title":"Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial","volume":"52","author":"Puolakka","year":"2005","journal-title":"Arthritis and Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD007649.pub4-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD007649.pub4-BIB0142|cit142","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007848.pub2","article-title":"Biologics for rheumatoid arthritis: an overview of Cochrane reviews","author":"Singh","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD007649.pub4-BIB0143|cit143","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008341","article-title":"Golimumab for rheumatoid arthritis","author":"Singh","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD007649.pub4-BIB0144|cit144","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008794.pub2","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","author":"Singh","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care and Research"},{"issue":"9990","key":"10.1002\/14651858.CD007649.pub4-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD007649.pub4-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care & Research"},{"issue":"3","key":"10.1002\/14651858.CD007649.pub4-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD007649.pub4-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/art.10731","article-title":"Functional disability in rheumatoid arthritis patients compared with a community population in Finland","volume":"48","author":"Sokka","year":"2003","journal-title":"Arthritis and Rheumatism"},{"issue":"20","key":"10.1002\/14651858.CD007649.pub4-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V","article-title":"Explaining heterogeneity in meta-analysis: a comparison of methods","volume":"18","author":"Thompson","year":"1999","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD007649.pub4-BIB0151|cit151","first-page":"360-6","article-title":"Extra-articular rheumatoid arthritis","volume":"23","author":"Turesson","year":"2013","journal-title":"Current Opinion in Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD007649.pub4-BIB0152|cit152","first-page":"41","article-title":"Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE","volume":"94","author":"Wong","year":"2006","journal-title":"Journal of the Medical Library Association"},{"issue":"2","key":"10.1002\/14651858.CD007649.pub4-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1547-5069.2006.00100.x","article-title":"Optimal CINAHL search strategies for identifying therapy studies and review articles","volume":"38","author":"Wong","year":"2006","journal-title":"Journal of Nursing Scholarship"},{"key":"10.1002\/14651858.CD007649.pub4-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/rheumatology\/keg231","article-title":"West Midlands Rheumatology Services and Training Committee. The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti-tumour necrosis factor therapy: an out-patient study","volume":"42","author":"Yee","year":"2003","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1002\/14651858.CD007649.pub4-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/rheumatology\/39.6.603","article-title":"How does functional disability in early rheumatoid arthritis affect patients and their lives? Results of 5 years of follow-up in 732 patients from the early RA study (ERAS)","volume":"39","author":"Young","year":"2000","journal-title":"Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD007649.pub4-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/jama.1991.03470010097038","article-title":"Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials","volume":"266","author":"Yusuf","year":"1991","journal-title":"JAMA"},{"issue":"11","key":"10.1002\/14651858.CD007649.pub4-BIB0157|cit157","first-page":"3870","article-title":"The efficacy and safety of certolizumab pegol (CZP) in the treatment of active rheumatoid arthritis (RA): a meta-analysis from nine randomized controlled trials","volume":"7","author":"Zhou","year":"2014","journal-title":"International Journal of Clinical and Experimental Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007649.pub4-BIB0158|cit158","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007649","article-title":"Certolizumab pegol (CDP870) for rheumatoid arthritis in adults","author":"Ruiz Garcia","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD007649.pub4-BIB0159|cit159","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007649.pub2","article-title":"Certolizumab pegol (CDP870) for rheumatoid arthritis in adults","author":"Ruiz Garcia","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD007649.pub4-BIB0160|cit160","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007649.pub3","article-title":"Certolizumab pegol (CDP870) for rheumatoid arthritis in adults","author":"Ruiz Garcia","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD007649.pub4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T16:56:14Z","timestamp":1750870574000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007649.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,9,8]]},"references-count":160,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007649.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,8]]}}}